Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: A survey of current 'next-step' practices

Steffany Jane Fredman, Maurizio Fava, Allison S. Kienke, Candace N. White, Andrew A. Nierenberg, Jerrold F. Rosenbaum

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Background: Many patients treated for major depression require more than one antidepressant trial to achieve or sustain response. However, the literature provides few treatment algorithms or effectiveness studies that empirically support 'next-step' options available to clinicians. We conducted a survey of psychiatrists and other medical specialists who treat depression to ascertain what clinicians actually do when faced with patients who suboptimally respond to an adequate course of selective serotonin reuptake inhibitor (SSRI) therapy. Method: Attendees at a psychopharmacology course (N = 801) were queried about their top choices for antidepressant-treatment nonresponders: a minimal responder after 4 weeks of adequate SSRI treatment, a partial responder after 8 weeks of adequate SSRI therapy, a nonresponder after 8 weeks of adequate SSRI therapy, and a relapser on long-term SSRI maintenance therapy. Choices included raising the dose, augmenting or combining with another agent, switching to a second SSRI, or switching to a non-SSRI agent. Results: 432 (54%) of the surveys were returned. Raising the dose was the most frequently reported next-step strategy for a patient with minimal response after 4 weeks of adequate SSRI therapy, partial response after 8 weeks of adequate SSRI therapy, and relapse on long-term SSRI therapy. Switching to a non-SSRI agent was the most frequently chosen option for non-responders to an adequate trial of SSRI therapy. Conclusion: Our findings suggest that clinicians select different next-step strategies when patients are nonresponders versus when patients are partial responders or relapsers.

Original languageEnglish (US)
Pages (from-to)403-408
Number of pages6
JournalJournal of Clinical Psychiatry
Volume61
Issue number6
DOIs
StatePublished - Jan 1 2000

Fingerprint

Serotonin Uptake Inhibitors
Depression
Recurrence
Therapeutics
Antidepressive Agents
Surveys and Questionnaires
Psychopharmacology
Psychiatry

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

Fredman, Steffany Jane ; Fava, Maurizio ; Kienke, Allison S. ; White, Candace N. ; Nierenberg, Andrew A. ; Rosenbaum, Jerrold F. / Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression : A survey of current 'next-step' practices. In: Journal of Clinical Psychiatry. 2000 ; Vol. 61, No. 6. pp. 403-408.
@article{a1fcc03849a54cb092c8a0c5555797f4,
title = "Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: A survey of current 'next-step' practices",
abstract = "Background: Many patients treated for major depression require more than one antidepressant trial to achieve or sustain response. However, the literature provides few treatment algorithms or effectiveness studies that empirically support 'next-step' options available to clinicians. We conducted a survey of psychiatrists and other medical specialists who treat depression to ascertain what clinicians actually do when faced with patients who suboptimally respond to an adequate course of selective serotonin reuptake inhibitor (SSRI) therapy. Method: Attendees at a psychopharmacology course (N = 801) were queried about their top choices for antidepressant-treatment nonresponders: a minimal responder after 4 weeks of adequate SSRI treatment, a partial responder after 8 weeks of adequate SSRI therapy, a nonresponder after 8 weeks of adequate SSRI therapy, and a relapser on long-term SSRI maintenance therapy. Choices included raising the dose, augmenting or combining with another agent, switching to a second SSRI, or switching to a non-SSRI agent. Results: 432 (54{\%}) of the surveys were returned. Raising the dose was the most frequently reported next-step strategy for a patient with minimal response after 4 weeks of adequate SSRI therapy, partial response after 8 weeks of adequate SSRI therapy, and relapse on long-term SSRI therapy. Switching to a non-SSRI agent was the most frequently chosen option for non-responders to an adequate trial of SSRI therapy. Conclusion: Our findings suggest that clinicians select different next-step strategies when patients are nonresponders versus when patients are partial responders or relapsers.",
author = "Fredman, {Steffany Jane} and Maurizio Fava and Kienke, {Allison S.} and White, {Candace N.} and Nierenberg, {Andrew A.} and Rosenbaum, {Jerrold F.}",
year = "2000",
month = "1",
day = "1",
doi = "10.4088/JCP.v61n0602",
language = "English (US)",
volume = "61",
pages = "403--408",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "6",

}

Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression : A survey of current 'next-step' practices. / Fredman, Steffany Jane; Fava, Maurizio; Kienke, Allison S.; White, Candace N.; Nierenberg, Andrew A.; Rosenbaum, Jerrold F.

In: Journal of Clinical Psychiatry, Vol. 61, No. 6, 01.01.2000, p. 403-408.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression

T2 - A survey of current 'next-step' practices

AU - Fredman, Steffany Jane

AU - Fava, Maurizio

AU - Kienke, Allison S.

AU - White, Candace N.

AU - Nierenberg, Andrew A.

AU - Rosenbaum, Jerrold F.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Background: Many patients treated for major depression require more than one antidepressant trial to achieve or sustain response. However, the literature provides few treatment algorithms or effectiveness studies that empirically support 'next-step' options available to clinicians. We conducted a survey of psychiatrists and other medical specialists who treat depression to ascertain what clinicians actually do when faced with patients who suboptimally respond to an adequate course of selective serotonin reuptake inhibitor (SSRI) therapy. Method: Attendees at a psychopharmacology course (N = 801) were queried about their top choices for antidepressant-treatment nonresponders: a minimal responder after 4 weeks of adequate SSRI treatment, a partial responder after 8 weeks of adequate SSRI therapy, a nonresponder after 8 weeks of adequate SSRI therapy, and a relapser on long-term SSRI maintenance therapy. Choices included raising the dose, augmenting or combining with another agent, switching to a second SSRI, or switching to a non-SSRI agent. Results: 432 (54%) of the surveys were returned. Raising the dose was the most frequently reported next-step strategy for a patient with minimal response after 4 weeks of adequate SSRI therapy, partial response after 8 weeks of adequate SSRI therapy, and relapse on long-term SSRI therapy. Switching to a non-SSRI agent was the most frequently chosen option for non-responders to an adequate trial of SSRI therapy. Conclusion: Our findings suggest that clinicians select different next-step strategies when patients are nonresponders versus when patients are partial responders or relapsers.

AB - Background: Many patients treated for major depression require more than one antidepressant trial to achieve or sustain response. However, the literature provides few treatment algorithms or effectiveness studies that empirically support 'next-step' options available to clinicians. We conducted a survey of psychiatrists and other medical specialists who treat depression to ascertain what clinicians actually do when faced with patients who suboptimally respond to an adequate course of selective serotonin reuptake inhibitor (SSRI) therapy. Method: Attendees at a psychopharmacology course (N = 801) were queried about their top choices for antidepressant-treatment nonresponders: a minimal responder after 4 weeks of adequate SSRI treatment, a partial responder after 8 weeks of adequate SSRI therapy, a nonresponder after 8 weeks of adequate SSRI therapy, and a relapser on long-term SSRI maintenance therapy. Choices included raising the dose, augmenting or combining with another agent, switching to a second SSRI, or switching to a non-SSRI agent. Results: 432 (54%) of the surveys were returned. Raising the dose was the most frequently reported next-step strategy for a patient with minimal response after 4 weeks of adequate SSRI therapy, partial response after 8 weeks of adequate SSRI therapy, and relapse on long-term SSRI therapy. Switching to a non-SSRI agent was the most frequently chosen option for non-responders to an adequate trial of SSRI therapy. Conclusion: Our findings suggest that clinicians select different next-step strategies when patients are nonresponders versus when patients are partial responders or relapsers.

UR - http://www.scopus.com/inward/record.url?scp=0033938763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033938763&partnerID=8YFLogxK

U2 - 10.4088/JCP.v61n0602

DO - 10.4088/JCP.v61n0602

M3 - Article

C2 - 10901336

AN - SCOPUS:0033938763

VL - 61

SP - 403

EP - 408

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 6

ER -